Profile data is unavailable for this security.
About the company
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
- Revenue in USD (TTM)1.44m
- Net income in USD-21.34m
- Incorporated2014
- Employees25.00
- LocationLongeveron Inc1951 NW 7th Ave, Ste 520MIAMI 33136United StatesUSA
- Phone+1 (305) 302-7158
- Fax+1 (302) 674-5266
- Websitehttps://www.longeveron.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liminatus Pharma Inc | 0.00 | -2.27m | 10.18m | -- | -- | -- | -- | -- | -0.0872 | -0.0872 | 0.00 | -0.0608 | 0.00 | -- | -- | -- | -77.46 | -- | -- | -- | -- | -- | -- | -- | -- | -12.30 | -- | -- | -- | -- | 28.85 | -- | -- | -- |
| Ainos Inc | 113.04k | -14.96m | 10.61m | 44.00 | -- | 0.7254 | -- | 93.89 | -4.29 | -4.29 | 0.0307 | 2.10 | 0.0042 | 0.12 | 3,768.00 | 2,569.09 | -55.34 | -38.46 | -60.63 | -55.22 | 82.62 | 35.93 | -13,231.35 | -1,122.70 | 2.67 | -19.92 | 0.5227 | -- | -83.02 | 12.06 | -7.93 | -- | 10.22 | -- |
| Soligenix Inc | 0.00 | -11.46m | 10.99m | 14.00 | -- | 1.41 | -- | -- | -3.66 | -3.66 | 0.00 | 0.7705 | 0.00 | -- | -- | 0.00 | -105.25 | -73.79 | -165.82 | -151.46 | -- | 22.19 | -- | -1,147.93 | -- | -- | 0.00 | -- | -85.78 | -51.89 | -34.62 | -- | -- | -- |
| Quince Therapeutics Inc | 0.00 | -56.98m | 11.14m | 36.00 | -- | 10.29 | -- | -- | -1.22 | -1.22 | 0.00 | 0.0194 | 0.00 | -- | -- | 0.00 | -48.20 | -42.95 | -55.60 | -46.33 | -- | -- | -- | -- | -- | -- | 0.943 | -- | -- | -- | -81.07 | -- | 36.12 | -- |
| KALA BIO Inc | 0.00 | -35.84m | 11.32m | 38.00 | -- | -- | -- | -- | -5.94 | -5.94 | 0.00 | -1.17 | 0.00 | -- | -- | 0.00 | -90.62 | -61.19 | -316.35 | -75.37 | -- | -- | -- | -1,732.87 | -- | -12.71 | 1.44 | -- | -- | -- | 8.74 | -- | -31.05 | -- |
| Longeveron Inc | 1.44m | -21.34m | 11.43m | 25.00 | -- | 1.13 | -- | 7.95 | -1.34 | -1.34 | 0.0909 | 0.4732 | 0.0632 | -- | 6.65 | 57,480.00 | -93.88 | -70.26 | -114.04 | -83.92 | 74.88 | 44.57 | -1,485.11 | -683.81 | -- | -- | 0.00 | -- | 237.38 | -15.76 | -10.86 | -- | 51.32 | -- |
| Sensei Biotherapeutics Inc | 0.00 | -24.14m | 11.47m | 14.00 | -- | 0.4983 | -- | -- | -19.16 | -19.16 | 0.00 | 18.24 | 0.00 | -- | -- | 0.00 | -59.72 | -43.45 | -68.03 | -48.13 | -- | -- | -- | -- | -- | -- | 0.0083 | -- | -- | -- | 11.57 | -- | 22.47 | -- |
| Inhibitor Therapeutics Inc | 0.00 | -3.43m | 11.56m | 3.00 | -- | 3,351.42 | -- | -- | -0.0199 | -0.0199 | 0.00 | 0.00002 | 0.00 | -- | -- | 0.00 | -71.49 | 17.96 | -72.49 | 20.49 | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | -- | -- | -10.35 | -- | -- | -- |
| Moleculin Biotech Inc | 0.00 | -41.36m | 11.69m | 17.00 | -- | -- | -- | -- | -55.88 | -55.88 | 0.00 | -13.60 | 0.00 | -- | -- | 0.00 | -189.07 | -49.52 | -254.72 | -54.93 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 26.89 | -- | -24.21 | -- |
| BioCardia Inc | 0.00 | -8.54m | 12.10m | 17.00 | -- | 4.60 | -- | -- | -1.73 | -1.73 | 0.00 | 0.2476 | 0.00 | -- | -- | 0.00 | -137.58 | -102.48 | -272.63 | -150.23 | -- | -- | -- | -1,938.01 | -- | -- | 0.00 | -- | -87.84 | -39.41 | 31.33 | -- | -47.18 | -- |
| Hookipa Pharma Inc | 9.35m | -73.31m | 12.33m | 82.00 | -- | 0.3542 | -- | 1.32 | -5.85 | -5.85 | 0.7457 | 2.82 | 0.0903 | -- | 1.74 | 114,036.60 | -70.79 | -40.82 | -91.08 | -50.56 | -- | -- | -784.01 | -266.20 | -- | -- | 0.00 | -- | 118.32 | 29.77 | 46.67 | -- | -37.28 | -- |
| GT Biopharma Inc | 0.00 | -9.33m | 12.36m | 1.00 | -- | 0.9355 | -- | -- | -3.38 | -3.38 | 0.00 | 0.4957 | 0.00 | -- | -- | 0.00 | -164.22 | -180.24 | -356.99 | -8,448.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -73.25 | -- | -- | -- |
| Kairos Pharma Ltd | 0.00 | -5.06m | 12.45m | 1.00 | -- | 1.62 | -- | -- | -0.3045 | -0.3045 | 0.00 | 0.3681 | 0.00 | -- | -- | 0.00 | -77.46 | -- | -92.07 | -- | -- | -- | -- | -- | -- | -94.05 | 0.00 | -- | -- | -- | -43.65 | -- | -- | -- |
| TRON Group Inc | 1.01m | -549.47k | 12.51m | 50.00 | -- | -- | -- | 12.39 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
| NewcelX AG | 0.00 | -6.21m | 12.63m | 1.00 | -- | 0.4081 | -- | -- | -20.39 | -20.39 | 0.00 | 6.94 | 0.00 | -- | -- | 0.00 | -78.31 | -232.34 | -- | -- | -- | -- | -- | -- | -- | -53.01 | 0.00 | -- | -- | -- | 66.67 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Longeveron Inc's reporting currency: US Dollar USD
4.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 460.41k | 2.32% |
| Geode Capital Management LLCas of 30 Sep 2025 | 141.50k | 0.71% |
| UBS Securities LLCas of 31 Dec 2025 | 60.21k | 0.30% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 56.60k | 0.29% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 45.38k | 0.23% |
| Jane Street Capital LLCas of 30 Sep 2025 | 43.94k | 0.22% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 38.72k | 0.20% |
| Capital Investment Advisory Services LLCas of 31 Dec 2025 | 26.53k | 0.13% |
| Commonwealth Equity Services LLCas of 30 Sep 2025 | 25.16k | 0.13% |
| Hamilton Point Investment Advisors LLCas of 30 Sep 2025 | 22.45k | 0.11% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
